San Antonio Breast Cancer Symposium 2025: Key Highlights

The 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted a significant shift in the surgical management of breast cancer, specifically focusing on the de-escalation of axillary lymph node procedures. This movement aims to reduce the extent of surgery in the underarm area for eligible patients without compromising oncologic safety or long-term survival rates.

According to reporting from Oncology Central, the symposium presentations underscored a growing clinical preference for more conservative approaches to the axilla. The primary goal of this de-escalation is to minimize the risk of surgical complications while maintaining the ability to accurately stage the cancer and provide necessary systemic treatment.

For decades, the standard of care for patients with lymph node-positive breast cancer involved axillary lymph node dissection (ALND). This procedure requires the removal of a significant number of lymph nodes from the axilla to ensure the cancer has not spread further and to reduce the risk of local recurrence.

However, the discussions at SABCS 2025 centered on the ability to avoid ALND in a broader range of patients through the use of sentinel lymph node biopsy (SLNB) and the strategic application of neoadjuvant chemotherapy.

Neoadjuvant chemotherapy refers to the administration of medication to shrink a tumor before the primary surgery. A critical point of discussion at the symposium was the concept of conversion, where patients who are initially diagnosed as node-positive may become node-negative following a successful response to chemotherapy.

When a patient achieves a pathologic complete response in the lymph nodes after neoadjuvant treatment, the necessity of a full ALND is called into question. Data presented at the symposium suggest that for these specific patients, a targeted axillary dissection or a sentinel lymph node biopsy may be sufficient to ensure the area is clear of disease.

The medical community is prioritizing this de-escalation primarily because of the high morbidity associated with ALND. The most significant concern is lymphedema, a chronic condition characterized by the accumulation of lymph fluid in the arm, which can lead to swelling, heaviness and an increased risk of infections.

By reducing the number of lymph nodes removed, clinicians aim to preserve the lymphatic drainage of the arm, thereby decreasing the incidence and severity of lymphedema and improving the overall quality of life for survivors.

The transition toward de-escalation is supported by a framework of precision medicine. Rather than applying a one-size-fits-all surgical approach, physicians are increasingly using imaging and pathology to identify which patients can safely undergo less invasive procedures.

The symposium highlighted that the decision to de-escalate must be carefully balanced. While avoiding ALND reduces side effects, the risk of leaving residual cancer in the axilla—known as false-negative rates—remains a primary concern for surgeons.

To mitigate this risk, the symposium discussed the importance of refined SLNB techniques and the use of dual-tracer mapping to increase the accuracy of node identification.

The findings presented at SABCS 2025 suggest that the integration of systemic therapy and targeted surgery allows for a more tailored treatment plan. This approach recognizes that for many patients, the systemic control provided by chemotherapy and targeted biologics reduces the reliance on aggressive local surgery for survival.

Despite the promising data on de-escalation, experts noted that long-term follow-up is essential. The medical community continues to monitor whether the omission of ALND in node-converted patients leads to any increase in regional recurrence over a ten-year period.

The consensus from the symposium indicates that the field is moving toward a future where the axilla is managed based on the individual biological response of the tumor rather than the initial diagnosis alone.